Kevin Bitterman
Partner @ Atlas Venture
Boston, United States
Kevin Bitterman is a Series B investor at Atlas Venture in Boston focused on Biotechnology and Therapeutics. Kevin is the interim president of Editas Medicine and a principal at Polaris Partners. He joined Polaris in 2004 and focuses on investments in health care. Kevin is a co-founder of Genocea Biosciences and Sirtris Pharmaceuticals (acquired by GSK) and was the founding CEO at Visterra Inc. (formerly Parasol Therapeutics). He currently representsPolaris as a director of InSeal Medical, Genocea Biosciences, Kala Pharmaceuticals, Neuronetics, Inc., Visterra Inc., Taris Biomedical and Vets First Choice. Additionally, he is a board observer to Arsenal Medical and 480 Biomedical.Kevin holds a Ph.D. in genetics from Harvard Medical School. His doctoral research focused on the molecular regulation of caloric restriction and on modulation of a novel class of protein deacetylases.
- Total investments:
- 28
- Last investment:
- Lead investor:
- 21%
Last updated:
For AI agents: llms.txt
Industries Kevin Bitterman invests in
Stages Kevin Bitterman invests in
Countries Kevin Bitterman invests in
Investment Focus
Industry
- Biotechnology 15 (54%)
- Therapeutics 9 (32%)
- Medical 7 (25%)
- Health Care 7 (25%)
- Pharmaceutical 4 (14%)
Stage
- Series B 8 (29%)
- Series A 6 (21%)
- Seed 3 (11%)
- Series C 3 (11%)
- Post-IPO Equity 2 (7%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Renasant Bio
|
Renasant Bio is a biopharmaceutical company pioneering disease-modifying oral small molecule treatments. | $54.5M / Seed / Jul 10, 2025 | |
Judo Bio
|
Judo Bio is a biotechnology company that develops precision therapeutics targeting specific cell populations to address genetic diseases. By leveraging its innovative receptor targeting approach, Judo Bio is developing a pipeline aimed at benefiting patients with both common and rare diseases. | $75M / Series A / Oct 07, 2024 | |
GRO Biosciences
|
GRO Biosciences is leveraging breakthrough technologies from computational protein design and synthetic biology to develop best-in-class protein therapeutics with enhanced properties. The company has established multiple genomically recoded strains of bacteria that can incorporate non-standard amino acids into proteins to confer increased potency,stability, and targeted delivery. GRO Biosciences is applying its technology platform to develop improved protein therapeutics for diabetes, growth disorders, and autoimmunity. The company, co-founded by Dr. George Church, is located at the Harvard Life Lab, shared laboratory space for high-potential life sciences and biotechnology startups founded by Harvard faculty, alumni, students, and postdoctoral scholars. | $60.3M / Series B / Jul 19, 2024 | |
Disc Medicine
|
Disc Medicine is led by an experienced team of scientists and industry experts, and supported by a panel of advisors with a strong track record of discovering and developing new and innovative therapies. Disc Medicine was founded by Atlas Venture and Brian MacDonald, with Novo Ventures and Access Biotechnology joining as additional investors. | $178M / Post-IPO Equity / Jun 14, 2024 | |
Remix Therapeutics
|
Remix Therapeutics is a biotechnology company that develops novel small molecule therapies designed to reprogram RNA processing and treat disease in entirely new ways. | $60M / Venture - Series Unknown / Jan 03, 2024 | |
|
Judo Bio
|
Judo Bio is a biotechnology company that develops precision therapeutics targeting specific cell populations to address genetic diseases. By leveraging its innovative receptor targeting approach, Judo Bio is developing a pipeline aimed at benefiting patients with both common and rare diseases. | $25M / Seed / Nov 21, 2023 | |
Mariana Oncology
|
Mariana Oncology is a biotechnology research industry. | $175M / Series B / Sep 07, 2023 | |
|
Remix Therapeutics
|
Remix Therapeutics is a biotechnology company that develops novel small molecule therapies designed to reprogram RNA processing and treat disease in entirely new ways. | $70M / Series B / May 17, 2022 | |
Curie Therapeutics
|
Curie Therapeutics is a fully integrated, next-generation radiopharmaceuticals company focused on pioneering a new class of targeted radiopharmaceuticals that are both safe and effective. Curie's radiopharmaceuticals are composed of rationally designed conjugates against carefully selected biological targets, to deliver alpha and beta-emittingradionuclide payloads. | $75M / Series A / Dec 01, 2021 | |
|
Mariana Oncology
|
Mariana Oncology is a biotechnology research industry. | $75M / Series A / Dec 01, 2021 | |
| See all 28 investments → | |||
Co-Investors
About Atlas Venture
Atlas Venture is an early-stage venture capital firm that creates and invests in biotech startup companies led by promising entrepreneurs focusing on life sciences innovation. Its seed-led venture creation strategy rigorously selects and focuses investment on compelling opportunities to build scalable businesses and realize value.
Atlas Venture Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Chelsea Place Johnson
Principal
|
|||
Ed Holson
Entrepreneur-in-Residence
|
|||
Jean-Francois Formela
Partner
|
|||
|
Kevin Bitterman
Partner
|
|||
Michael Gladstone
Principal
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Kevin Bitterman invest in?
Kevin Bitterman invests primarily in Biotechnology, Therapeutics and Medical startups, most often at Series B and Series A stage. Most of the 28 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Kevin Bitterman last invest?
The most recent investment recorded for Kevin Bitterman closed in Jul 2025. Shizune tracks 28 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
